Biotech Business - May 18, 2022
Immunovia Inc achieves Clinical Laboratory Licensure
The Rhode Island Department of Health has granted Immunovia, Inc., the US subsidiary of Immunovia, Clinical Laboratory licensure. The licensure allows physicians in Rhode Island to order the IMMray PanCan-d test for their patients. “Receiving licensure in Rhode Island now allows us to offer IMMray PanCan-d in 46 states. We expect additional state licensures to […]
In a new job - May 16, 2022
Immunovia appoints Head of Market Access US
The company has appointed Natalie Carfora as Head of Market Access of its US subsidiary, Immunovia, Inc. Natalie Carfora brings deep expertise to the reimbursement process from prior market access roles at Scipher Medicine and Myriad Genetics, states Immunovia. She will take up her position on May 23, 2022. “The hire of Natalie as Head […]
In a new job - March 30, 2022
Immunovia appoints CEO of its US subsidiary
Immunovia has appointed Jeff Borcherding as CEO of its US subsidiary Immunovia, Inc. Jeff Borcherding will be part of the Immunovia group management team from April 11. “I’m very pleased that Jeff Borcherding will join Immunovia. Jeff’s appointment further accelerates the US commercialization efforts of IMMray PanCan-d and is in-line with our strategic priority to […]
In a new job - December 1, 2021
Immunovia’s CEO to step down
Immunovia has announced that the company’s President and Chief Executive Officer, Patrik Dahlen, has informed the Board of Directors of his intention to step down, for personal reasons. The search for a new CEO will start immediately, states the company. Patrik Dahlen will remain with the company for another six months to ensure an orderly […]
Pharma Award - October 29, 2021
Immunovia receives Presidential Poster Award
Immunovia has announced that Thomas King, MD, PhD, Medical Director of Immunovia, Inc. was awarded the Presidential Poster Award at the American College of Gastroenterology (ACG) Annual Scientific Meeting for the blind validation results for the IMMray PanCan-d test. The abstract reports the results of Immunovia, Inc.’s blind validation study, demonstrating that the IMMray PanCan-d […]
Agreement - September 14, 2021
Immunovia enters licensing agreement with JW BioScience
Immunovia has strengthened its patent protection for pancreatic cancer biomarkers by obtaining a global license from the South Korean company JW BioScience’s IP portfolio. The license agreement gives Immunovia global commercial rights for two biomarkers for early detection of pancreatic cancer. The biomarkers are also part of Immunovia, Inc.’s IMMray PanCan-d biomarker signature. Immunovia discovered […]
